Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A phase III randomized trial

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3141-3148

  Byrne, Michael J ^a   Gebskl, V ^a   Forbes, J ^a   Tattersall, M H ^a   Simes, R J ^a   Coates, A S ^a   Dewar, J ^a   Lunn, M ^a   Flower, C ^a   Gill, P G ^a   Stewart, J ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

EID: 0030814481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3141     Document Type: Article

References (28)

1. Harnett PR, Kirsten F, Tattersall MHN: Drug resistance in clinical practice: Patterns of treatment failure in advanced breast and ovarian cancer. J Clin Oncol 4:952-957, 1986
2. Harnett PR, Tattersall MHN, Coates AS, et al, for the Australian and New Zealand Trials Group: Drug resistance in clinical practice: Patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. Eur J Cancer Clin Oncol 23:1601-1605, 1987
3. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
4. Mantle N: Evaluation of survival data and two new rank order statistics in its consideration. Cancer Chemotherapy Rep 50:163-170, 1966
5. Cox DR: Regression models and life-tables. J Royal Stat Soc B 34:187-202, 1972
6. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Amer Statist Assoc 47:501-515, 1958
7. Lunn M, McNeil DR: Applying Cox regression to competing risks. Biometrics 52:524-532, 1995
8. Pepe MS: Inference with dependent risks in multiple end-point studies. J Amer Statist Assoc 86:770-778, 1991
9. Gill PG, Gebski V, Snyder R, et al: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 4:741-744, 1993
10. Mouridsen HT, Ellemann K, Mattsson W, et al: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171-175, 1979
11. Trodella L, Ausilli-Cetaro CP, Turriziani E, et al: Combination therapy with progestins and tamoxifen in advanced breast cancer. Am J Clin Oncol 5:495-499, 1982
12. van Veelen H, Willemsse PHB, Tjabbes T, et al: Oral high dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trail in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986
13. Paterson AHG, Hanson J, Pritchard KI, et al: Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 17:52-62, 1990 (suppl 9)
14. Katzenellenbogen BS: Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83:1434-1435, 1991
15. Osborne CK, Fuqua SAW: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32:49-55, 1994
16. Encarnacion CA, Ciocca DR, McGuire WL, et al: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246, 1993
17. Johnston SR, Saccani-Jotti G, Smith IE, et al: Changes in estrogen receptor, progesterone receptor and PS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331-3338, 1995
18. Osborne CK, Wiebe VJ, McGuire WL, et al: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen resistant tumors from breast cancer patients. J Clin Oncol 10:304-310, 1992
19. Johnston SR, Dowsett M, Smith IE: Toward a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 3:503-511, 1992
20. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196, 1987
21. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long term antiestrogen administration. Cancer Res 48:5183-5187, 1988
22. Graham ML, Smith JA, Jewett PB, et al: Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: Analysis by quantitative dual parameter flow cytology. Cancer Res 52:593-602, 1992
23. Hoogstraten B, Gad-el-Mawla N, Malony TR, et al: Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 54:2248-2256, 1984
24. Sawka CA, Pritchard KI, Paterson AHG, et al: Role and mechanism of action of tamoxifen in premenopausal women with breast carcinoma. Cancer Res 46:3152-3156, 1986
25. Planting AST, Alexieva-Figusch J, Blonk-v.d. Wijst J, van Putten WLJ: Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69:363-368, 1985
26. Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet 1:36, 1987
27. Howell A, Dodwell DJ, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617, 1992
28. Birrell SN, Roder DM, Horsfall DJ, et al: Medroxyprogesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression. J Clin Oncol 13:1572-1577, 1995